Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Zebularine has antimitogenic and chemosensitizing effects in ovarian cancer
December 15th, 2005
According to recent research from the United States published in the journal Molecular Cancer Therapeutics, the methylation inhibitor zebularine has antimitogenic and chemosensitizing effects in ovarian cancer. "Deoxycytosine methylation within CpG islands of tumor suppressor genes plays a prominent role in the development and progression of drug-resistant ovarian cancer." "Consequently," wrote C. Balch and colleagues, Indiana University, "epigenetic therapies directed toward tumor suppressor demethylation/reexpression could potentially reverse malignant phenotypes and chemosensitize recalcitrant tumors." "In this report,...
Source: Women's Health Weekly (2005-12-15)
|
